Schizophrenia

The proportion of schizophrenia cases linked to cannabis use disorder increased three- to fourfold in the past 2 decades, according to results of a nationwide prospective cohort study published in JAMA Psychiatry.

Individuals with mental disorders, particularly those with schizophrenia, received less screening and lower-quality treatment for cardiovascular disease, according to results of a systematic review and meta-analysis.

Groups with shorter fetal maturity at birth had slightly higher rates of multiple neuropsychiatric disorders while groups with the longest fetal maturity exhibited the lowest rates for most disorders.

Patients with antipsychotic-naive and first-episode schizophrenia who received antipsychotic treatment experienced weight gain and improvement of clinical symptoms following 8 weeks of treatment.

Among patients with schizophrenia spectrum disorders, women had poorer subjective recovery-related outcomes and more unmet needs compared with men, according to study results published in Journal of Clinical Psychiatry.

An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of risperidone over 1-week dosing intervals, according to results of a randomized, parallel group, placebo-controlled study.

The FDA has approved an olanzapine/samidorphan combination treatment for schizophrenia and bipolar 1 disorder in adults.

Anticholinergic medication burden is substantial among individuals with schizophrenia, according to results of a cross-sectional data analysis published in American Journal of Psychiatry.

Medicare patients with schizophrenia had increased risk for suicide, with young adults having the highest absolute and relative risk, according to study results published in JAMA Psychiatry.

A video-based intervention for young adults appeared effective at humanizing schizophrenia and reducing stigma surrounding the diagnosis, according to results of a randomized controlled trial published in American Journal of Psychiatry.